Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 January-February;178(1-2) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 January-February;178(1-2):1-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 January-February;178(1-2):1-8

DOI: 10.23736/S0393-3660.18.03709-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Concomitant use of policosanol and antiplatelet drugs in older patients

Julio C. FERNÁNDEZ-TRAVIESO 1 , José ILLNAIT-FERRER 1, Lilia FERNÁNDEZ-DORTA 1, Rosa MÁS-FERREIRO 1, Sarahí MENDOZA-CASTAÑO 1, Ernesto LÓPEZ-GONZÁLEZ 2, Rafael GÁMEZ-MENÉNDEZ 1, Meilis MESA-ANGARICA 2

1 National Center for Scientific Research, Havana, Cuba; 2 Surgical Medical Research Center, Havana, Cuba



BACKGROUND: The objective of the present analysis as a part of a prevention study, we investigated whether policosanol administered to older individuals taking antiplatelet drugs supposes concern regarding to potential risk for adverse drug-drug interactions.
METHODS: We randomized 1470 elderly patients at high coronary risk to policosanol 5 mg/day or placebo for 3 years. For this analysis, the records of all patients (N.=334) taking antiplatelet drugs were included. Analysis was by intention-to-treat.
RESULTS: After one year, policosanol decreased significantly low-density lipoprotein-cholesterol (LDL-C) (21.0%), total cholesterol (16.9%) and triglycerides (19.6%), while raised high-density lipoprotein-cholesterol (HDL-C) (6.2%). Policosanol effects were maintained, even improved, during the follow-up. At study completion policosanol lowered LDL-C (34.3%), total cholesterol (23.9%), triglycerides (22.2%) and raised HDL-C (14.5%). Sixty patients (41 placebo, 19 policosanol, P<0.01) withdrew from the study, 33 (23 placebo, 10 policosanol) (P<0.01) due to some adverse event, all serious. Policosanol did not impair safety indicators and did not increase any adverse event respect to placebo.
CONCLUSIONS: The policosanol can be administered to older patients taking antiplatelet drugs without risk of relevant adverse drug-drug interactions.


KEY WORDS: Policosanol - Platelet aggregation inhibitors - Aged - Drug interactions - Drug-related side effects and adverse reactions

inizio pagina